An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Eur Respir J. 2017;49:1700214.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21:345–355.
   PubMed Web of Science ®Google Scholar
• Anderson GP Advances in understanding COPD. F1000Res. 2016;5; F1000 Faculty Rev-2392.
   Google Scholar
• Segreti A, Stirpe E, Rogliani P, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18:381–388.
   PubMed Web of Science ®Google Scholar
• Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69:857–864.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419.
   PubMed Web of Science ®Google Scholar
• Singh D, Roche N, Halpin D, et al. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:541–549.
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11:54–65.
   PubMedGoogle Scholar
• Cazzola M, Beeh KM, Price D, et al. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulm Pharmacol Ther. 2015;31:68–78.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med. 2014;35:191–201.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181–1196.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids. Evid Based Med. 2017;22:183–184.
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Novelli L, et al. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14:2489–2499.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P. LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. Evid Based Med. 2016;21:222.
   PubMedGoogle Scholar
• Cazzola M, Lopez-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J. 2013;42:885–887.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438–446.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–973.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–1929.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Puxeddu E. Dual bronchodilation and exacerbations of COPD. J Thorac Dis. 2016;8:2383–2386.
   PubMed Web of Science ®Google Scholar
• Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis. 2017;12:2291–2305.
   PubMed Web of Science ®Google Scholar
• Boardman C, Chachi L, Gavrila A, et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther. 2014;29:129–143.
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40:724–741.
   PubMed Web of Science ®Google Scholar
• Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol. 2008;294:L612–31.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment – difficulties of and barriers to drug development. Lancet. 2011;378:1027–1037.
   PubMed Web of Science ®Google Scholar
• Luo J, Wang K, Liu D, et al. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Respir Res. 2016;17:18.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cazzola M, et al. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15:1133–1146.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease. What does the future hold? Drugs. 2014;74:1983–1992.
   PubMed Web of Science ®Google Scholar
• Spina D, Page CP. Xanthines and phosphodiesterase inhibitors. Handb Exp Pharmacol. 2017;237:63–91.
   PubMedGoogle Scholar
• Horita N, Miyazawa N, Kojima R, et al. Chronic use of theophylline and mortality in chronic obstructive pulmonary disease: a meta-analysis. Arch Bronconeumol. 2016;52:233–238.
   PubMed Web of Science ®Google Scholar
• Page CP. Doxofylline: a “novofylline”. Pulm Pharmacol Ther. 2010;23:231–234.
   PubMed Web of Science ®Google Scholar
• Van Mastbergen J, Jolas T, Allegra L, et al. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther. 2012;25:55–61.
   PubMed Web of Science ®Google Scholar
• Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10:e0121257.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
   PubMed Web of Science ®Google Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590–615.
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017;11:147–155.
   PubMed Web of Science ®Google Scholar
• Balloy V, Deveaux A, Lebeaux D, et al. Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol. 2014;171:1783–1794.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med. 2008;102:321–327.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Capuano A, Rogliani P, et al. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012;12:300–308.
   PubMed Web of Science ®Google Scholar
• Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J. 2001;8:27–33.
   PubMedGoogle Scholar
• Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012;25:62–68.
   PubMed Web of Science ®Google Scholar
• Braido F, Melioli G, Cazzola M, et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced immunological approach in COPD exacerbation). Pulm Pharmacol Ther. 2015;33:75–80.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Lynch SV. The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev Respir Med. 2011;5:809–821.
   PubMed Web of Science ®Google Scholar
• Dy R, Sethi S. The lung microbiome and exacerbations of COPD. Curr Opin Pulm Med. 2016;22:196–202.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10:89–97.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. Copd. 2017. DOI:10.1080/15412555.2017.1347918.
   Google Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24:451–461.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. N-acetylcysteine in COPD may be beneficial, but for whom? Lancet Respir Med. 2014;2:166–167.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50:1700711.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494–1498.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. Copd. 2009;6:177–184.
   PubMedGoogle Scholar
• McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5:51–60.
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res. 2017;18:105.
   PubMed Web of Science ®Google Scholar
• Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. Copd. 2013;10(Suppl 1):26–34.
   PubMedGoogle Scholar
• Memoranda/memorandum. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397–415.
   PubMed Web of Science ®Google Scholar
• Hatipoğlu U, Stoller JK. α1-Antitrypsin deficiency. Clin Chest Med. 2016;37:487–504.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Alpha1-antitrypsin review. Clin Chest Med. 2014;35:39–50.
   PubMed Web of Science ®Google Scholar
• Teschler H. Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev. 2015;24:46–51.
   PubMed Web of Science ®Google Scholar
• Janciauskiene S, Welte T. Well-known and less well-known functions of alpha-1 antitrypsin. Its role in chronic obstructive pulmonary disease and other disease developments. Ann Am Thorac Soc. 2016;13(Suppl 4):S280–8.
   PubMedGoogle Scholar
• Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80:112–119.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–969.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010;7:e1000220.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rinaldi B, et al. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012;12:315–322.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3:593–595.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rinaldi B, et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017;77:721–732.
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145:695–703.
   PubMed Web of Science ®Google Scholar
• Curtis KJ, Meyrick VM, Mehta B, et al. Angiotensin-converting enzyme inhibition as an adjunct to pulmonary rehabilitation in COPD. Am J Respir Crit Care Med. 2016;194:1349–1357.
   PubMed Web of Science ®Google Scholar
• Cao C, Wu Y, Xu Z, et al. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research. Sci Rep. 2015;5:16461.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol. 2011;45:704–710.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210.
   PubMed Web of Science ®Google Scholar
• Citgez E, Van Der Palen J, Koehorst-Ter Huurne K, et al. Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study. BMJ Open Respir Res. 2016;3:e000142.
   PubMed Web of Science ®Google Scholar
• Rossi A, Inciardi RM, Rossi A, et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther. 2017;44:16–23.
   PubMed Web of Science ®Google Scholar
• Neukamm A, Hoiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med. 2015;278:59–67.
   PubMed Web of Science ®Google Scholar
• Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9:e113048.
   PubMed Web of Science ®Google Scholar
• Rinaldi B, Capuano A, Gritti G, et al. Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther. 2014;28:109–113.
   PubMed Web of Science ®Google Scholar
• Rinaldi B, Donniacuo M, Sodano L, et al. Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015;172:3627–3637.
   PubMed Web of Science ®Google Scholar
• Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:715–720.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71:8–14.
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Pollina A, et al. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014;69:80–81.
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, d’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. Copd. 2016;13:509–514.
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Targeting mechanisms linking COPD to type 2 diabetes mellitus. Trends Pharmacol Sci. 2017;38:940-951.
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006.
   PubMed Web of Science ®Google Scholar
• Schaafsma D, Gosens R, Ris JM, et al. Insulin induces airway smooth muscle contraction. Br J Pharmacol. 2007;150:136–142.
   PubMed Web of Science ®Google Scholar
• Schaafsma D, McNeill KD, Stelmack GL, et al. Insulin increases the expression of contractile phenotypic markers in airway smooth muscle. Am J Physiol Cell Physiol. 2007;293:C429–39.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol. 2012;47:509–516.
   PubMed Web of Science ®Google Scholar
• Rinne ST, Liu CF, Feemster LC, et al. Thiazolidinediones are associated with a reduced risk of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2015;10:1591–1597.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Capuani B, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55:804–814.
   PubMed Web of Science ®Google Scholar
• Mirza S, Benzo R. Chronic obstructive pulmonary disease phenotypes: implications for care. Mayo Clin Proc. 2017;92:1104–1112.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015;75:1575–1585.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Subramanian DR, Gupta S, Burggraf D, et al. Emphysema- and airwaydominant COPD phenotypes defined by standardised quantitative computed tomography. Eur Respir J. 2016;48:92–103.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Venturelli E, Biscione G, et al. Exercise performance after standard rehabilitation in COPD patients with lung hyperinflation. Intern Emerg Med. 2014;9:23–31.
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma and global initiative for chronic obstructive lung disease diagnosis of diseases of chronic airflow limitation: asthma, COPD, and asthma-COPD overlap syndrome (ACOS) [ Accessed 2017 Oct 17]. Available from: http://goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/.
   Google Scholar
• Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016;138:977–983.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, Van Zyl-Smit RN, et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719–728.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Ora J, et al. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2016;17:977–988.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10:110–120.
   Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5:747–759.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Puxeddu E, et al. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117–123.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J Comp Eff Res. 2017. DOI:10.2217/cer-2017-0037
   PubMedGoogle Scholar
• Singh D. Evaluation of new drugs for asthma and COPD: endpoints, biomarkers and clinical trial design. Handb Exp Pharmacol. 2017;237:243–264.
   PubMedGoogle Scholar
• Ross CL, Hansel TT. New drug therapies for COPD. Clin Chest Med. 2014;35:219–239.
   PubMed Web of Science ®Google Scholar